The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nikonov E.L.

FGBU "Poliklinika #1" Upravleniia delami Prezidenta RF

Aksenov V.A.

Vice-president of the Inter-Regional Association of Evidence-Based Medicine, Orenburg, Russia

Current approaches to diagnosing and treating nonalcoholic fatty liver disease

Authors:

Nikonov E.L., Aksenov V.A.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2018;21(3): 62‑69

DOI: 10.17116/profmed201831262

Views: 19046

Downloaded: 627

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Nikonov EL, Aksenov VA. Current approaches to diagnosing and treating nonalcoholic fatty liver disease. Russian Journal of Preventive Medicine. 2018;21(3):62‑69. (In Russ.)
https://doi.org/10.17116/profmed201831262

 
МСФ на ЯМ
Close metadata
Recommended articles:
Impact of meta­bolic para­meters and risk factors on surfactant proteins SP-A and SP-D in abdo­minal obesity. Russian Journal of Preventive Medi­cine. 2024;(7):60-66
Clinical consequences of sarcopenic obesity. Part 1. Non-alcoholic fatty liver disease, type 2 diabetes mellitus, chro­nic kidney disease. Russian Journal of Preventive Medi­cine. 2024;(8):114-120
Serum uric acid — a meta­bolic marker of non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):36-42
Insu­lin resi­stance as a cardiovascular risk factor in patients with ulce­rative coli­tis. Russian Journal of Evidence-Based Gastroenterology. 2024;(3):42-49
Surgical treatment of macromastia in benign breast dysplasia and como­rbidities. Plastic Surgery and Aesthetic Medi­cine. 2024;(4-2):5-13
Multiparametric ultrasound effe­ctiveness in dete­cting and moni­toring non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):25-33
Liver and bone in tandem: osteopenia as an inevitable companion to non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):40-50
Hepa­tocellular carcinoma asso­ciated with nona­lcoholic fatty liver disease. P.A. Herzen Journal of Onco­logy. 2024;(6):57-62
Effe­ctiveness of using preventive and personalized technologies for obesity correction. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6-2):80-90

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide, although there are no accurate data on its prevalence and incidence due to its asymptomatic course and different diagnostic criteria. NAFLD is an umbrella term that includes two main morphological types: non-alcoholic fatty hepatosis and non-alcoholic steatohepatitis. The basis for the pathogenesis of NAFLD is insulin resistance and hyperinsulinemia, which cause obvious disorders of lipid and carbohydrate metabolism and an imbalance between lipid consumption and utilization. NAFLD is usually characterized by an asymptomatic course and is often diagnosed accidentally when a patient visits his doctor for hypertension, coronary heart disease, peripheral vascular diseases, obesity, type 2 diabetes, etc.

Keywords:

non-alcoholic fatty liver disease
non-alcoholic fatty hepatosis
non-alcoholic steatohepatitis
steatosis
insulin resistance

Authors:

Nikonov E.L.

FGBU "Poliklinika #1" Upravleniia delami Prezidenta RF

Aksenov V.A.

Vice-president of the Inter-Regional Association of Evidence-Based Medicine, Orenburg, Russia

List of references:

  1. Torres DM, Harrison SA. Nonalcoholic Fatty Liver Disease. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Eds. Feldman M, Friedman LS, Brandt LJ. Pathophysiology, Diagnosis, Management. 2015;10.
  2. Calzadilla BL, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17(5):774. https://doi.org/10.3390/ijms17050774
  3. Kanwar P, Kowdley KV. The metabolic syndrome and its influence on nonalcoholic steatohepatitis. Clin Liver Dis. 2016;20(2):225-243. https://doi.org/10.1016/j.cld.2015.10.002
  4. Sayiner M, Koenig A, Henry L, Yonnossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the World. Clin Liver Dis. 2016;20(2):205-214. https://doi.org/10.1016/j.cld.2015.10.001
  5. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. https://doi.org/10.1016/j.jhep.2015.11.004
  6. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53(2):372-384. https://doi.org/10.1016/j.jhep.2010.04.008
  7. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112-117. https://doi.org/10.7326/0003-4819-132-2-200001180-00004
  8. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. https://doi.org/10.1002/hep.28431
  9. Lazebnik LB, Radchenko VG, Golovanova YeV, Zvenigorodskaya LA, Konev YuV, Seliverstov PV, Sitkin SI, Tkachenko YeI, Avalueva YeB, Ailamazyan EK, Vlasov NN, Grinevich VB, Kornienko YeA, Novikova VP, Khoroshinina LP, Zhestkova NV, Oreshko LS, Dudanova OP, Dobritsa VP, Turieva LV, Tirikova OV, Kozlova NM, Yeliseev SM, Gumerov RR, Ventsak YeV, Aleshina YeI, Gurova MM, Goryacheva LG. Nonalcoholic fatty liver disease: clinic, diagnostics, treatment (guidelines for the specialists on internal medicine, 2nd version). Therapy. 2017;3(13):6-23. (In Russ.)
  10. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology. 2010;52(3):1156-1161. https://doi.org/10.1002/hep.23789
  11. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi MA, Cersosimo E, Ferrannini E, DeFronzo RA. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007;133(2):496-506. https://doi.org/10.1053/j.gastro.2007.04.068
  12. Kotronen A, Juurinen I, Hakkarainen A, Westerbacka J, Corner A, Bergholm R, Yki-Jarvinen H. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008;31(1):165-169. https://doi.org/10.2337/dc07-1463
  13. Lonardo A, Bellentani S, Argo CK, Ballestn S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, Targher G. Epidemiological modifiers of non-alcoholic fatty fiver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47(12):997-1006. https://doi.org/10.1016/j.dld.2015.08.004
  14. Sung КС, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty fiver, over five years of follow-up and risk of incident hypertension. J Hepatol. 2014;60(5):1040-1045. https://doi.org/10.1016/j.jhep.2014.01.009
  15. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-285. https://doi.org/10.1111/j.1365-2036.2011.04724.x
  16. Loomba R, Abraham M, Unalp A, Wilson L, Irvine J, Doo E, Bass NM, the NonalcoholicSteatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56(3):943-951. https://doi.org/10.1002/hep.25772
  17. Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvin-en H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J PhysiolEndocrinol-Metab. 2007;292(3): E829-E835. https://doi.org/10.1152/ajpendo.00133.2006
  18. Llaurado G, Sevastianova K, Sadevirta S, Hakkarainen A, Lundbom N, Orho-Melander M, Groop P-H, Forsblom C, Yki-Järvinen. Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes. J Clin Endocrinol-Metab. 2015;100(2):607-616. https://doi.org/10.1210/jc.2014-3050
  19. Kalia HS, Gaglio PJ. The prevalence and pathobiology of nonalcoholic fatty liver disease in patients of different races or ethnicities. Clin Liver Dis. 2016;20(2):215-224. https://doi.org/10.1016/j.cld.2015.10.005
  20. Mohanty SR, Troy TN, Huo D, O’Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol. 2009;50(4):797-804. https://doi.org/10.1016/j.jhep.2008.11.017
  21. Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35(03):221-235. https://doi.org/10.1055/s-0035-1562943
  22. Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. IntJ Cardiol. 2013;167(4):1109-1117. https://doi.org/10.1016/j.ijcard.2012.09.085
  23. Andersen CJ, Fernandez ML. Dietary strategies to reduce metabolic syndrome. Rev Endocr Metab Disord. 2013;14(3):241-254. https://doi.org/10.1007/s11154-013-9251-y
  24. Godos J, Federico A, Dallio M, Scazzina F. Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. Int J Food Sci Nutr. 2017;68(1):18-27.https://doi.org/10.1080/09637486.2016.1214239
  25. Hamabe A, Uto H, Imamiira Y, Kusano K, Mawatari S, Kiunagai К, Kiire T, Tamai T, Moriiiclii A, Sakiyania T, Oketani M, Ido A, Tsubouchi H. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J Gastiventerol. 2011;46(6):769-778. https://doi.org/10.1007/s00535-011-0376-z
  26. Targher G, Alberiche M, Zenere MB, Bonadonna RC, Muggeo M, Bonora E. Cigarette smoking and insulin resistance in patients with noninsulm-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82(11):3619-3624. https://doi.org/10.1210/jcem.82.11.4351
  27. Ronnemaa T, Ronnemaa EM, Puukka P, Pyorala K, Laakso M. Smoking is independently associated with high plasma insulin levels in nondiabetic men. Diabetes Care.1996;19(11):1229-1232. https://doi.org/10.2337/diacare.19.11.1229
  28. Carnetlion MR, Fortmann SP, Palaniappan L, Duncan BB, Sclunidt MI, Chambless LE. Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study. 1987-1998. Am J Epidemiol. 2003;158(11):1058-1067. https://doi.org/10.1093/aje/kwg260
  29. Weitzman M, Cook S, Aiiinger P, Florin ТА, Daniels S, Nguyen M, WinickofF JP. Tobacco smoke exposure is associated with tlie metabohc syndrome in adolescents. Circulation. 2005;112(6):862-869. https://doi.org/10.1161/circulationaha.104.520650
  30. Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T, Takano Y, Ueno T, Koga H, George J, Shiba N, Torimura T. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017;66(1):142-152. https://doi.org/10.1016/j.jhep.2016.08.023
  31. Macut D, Tzioinalos K, Bozic-Antic L, Bjekic-Macut J, Katsikis L, Papadakis E, Andric Z, Panidis D. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod. 2016;31(6):1347-1353. https://doi.org/10.1093/humrep/dew076
  32. Kalial H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2014;81(4):523-528. https://doi.org/10.1111/cen.12369
  33. Yassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, Tzavara I. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod. 2010;25(1):212-220. https://doi.org/10.1093/humrep/dep380
  34. Markon A, Androulakis II, Mounnouris C, Tsikkini A, Samara C, Sougioultzis S, Piaditis G, Kaltsas G. Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertil Steril. 2010;93(4):1220-1226. https://doi.org/10.1016/j.fertnstert.2008.12.008
  35. Kauffman RP, Baker ТЕ, Baker V, Kauffinan MM, Castracane VD. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol. 2010;26(1):39-46. https://doi.org/10.3109/09513590903184084
  36. Paschetta E, Belci P, Alisi A, Liccardo D, Cutrera R, Musso G, Nobili V. OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Injlamm. 2015;2015:1-10. https://doi.org/10.1155/2015/815721
  37. Tanne F, Gagnadoux F, Chazouilleres O, Fleury B, Wendum D, Lasnier E, Lebeau B, Poupon R, Serfaty L. Chronic liver injury during obstructive sleep apnea. Hepatology. 2005;41(6):1290-1296. https://doi.org/10.1002/hep.20725
  38. Campos GM, Bambha K, Vittinglioff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47(6):1916-1923. https://doi.org/10.1002/hep.22241
  39. Aron-Wisnewsky J, Minville C, Tordjinan J, Levy P, Bouillot JL, Basdevant A, Bedossa P, Clement K, Pepin JL. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol. 2012;56(1):225-233. https://doi.org/10.1016/j.jhep.2011.04.022
  40. Mishra P, Nugent C, Afendy A, Bai C, Bhatia P, Afendy M, Fang Y, Elariny H, Goodman Z, Younossi ZM. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Lh’er bit. 2008;28(8):1080-1086. https://doi.org/10.1111/j.1478-3231.2008.01822.x
  41. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol-Hepatol. 2013;10(6):330-344. https://doi.org/10.1038/nrgastro.2013.41
  42. Akuta N, Kawamura Y, Arase Y, Suzuki F, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Dceda K, Kumada H. Relationships between genetic variations of PNPLA3, TM6SF2 and histological features of nonalcoholic fatty liver disease in Japan. Gut Liver. 2016;10(3): 437-445. https://doi.org/10.5009/gnl15163
  43. Kanth W, Sasikala M, Rao PN, Steffie Avanthi U, Rao KR, Nageshwar Reddy D. Pooled genetic analysis in ultrasound measured non-alcoholic fatty liver disease in Indian subjects: a pilot study. World J Hepatol. 2014;6(6):435-442. https://doi.org/10.4254/wjh.v6.i6.435
  44. Bhatt SP, Nigam P, Misra A, Guleria R, Pandey RM, Qadar Pasha MA. Genetic variation in the patatin-like phospholipase domain-containing protein-3 (PNPLA-3) gene in Asian Indians with nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2013;11(5):329-335. https://doi.org/10.1089/met.2012.0064
  45. Zhang Y, C’ai W, Song J, Miao L, Zhang B, Xu Q, Zhang L, Yao H. Association between the PNPLA3 I148M polymorphism and non-alcoholic fatty liver disease in the Uygur and Han ethnic groups of northwestern China. PLoS One. 2014;9(10):el08381. https://doi.org/10.1371/journal.pone.0108381
  46. Singal AG, Manjimatli H, Yopp AC, Beg MS, Marrero JA, Gopal P, Waljee AK. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a metaanalysis. Am J Gastmenterol. 2014; 109(3):325-334. https://doi.org/10.1038/ajg.2013.476
  47. Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison MED, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309. https://doi.org/10.1038/ncomms5309
  48. Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, Motta BM, Kaminska D, Rametta R, Grimaudo S, Pelusi S, Montalcini T, Alisi A, Maggioni M, Kärjä V, Borén J, Käkelä P, Di Marco V, Xing C, Nobili V, Dallapiccola B, Craxi A, Pihlajamäki J, Fargion S, Sjöström L, Carlsson LM, Romeo S, Valenti L. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61(2):506-514. https://doi.org/10.1002/hep.27490
  49. Me Cullough AJ. The epidemiology and risk factors of NASH. Hepatology. 2013;58(5):1644-1654.
  50. Moschetta A, Modica S, Gadaleta KM. Modulation of nuclear bile acid receptor FXR activity m the gut - liver axis. Nucl Recept Signal. 2010;8:e005.
  51. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L, Orho–Melander M, Yki–Järvinen H. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137(3):865-872. https://doi.org/10.1053/j.gastro.2009.06.005
  52. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42(1):132-138. https://doi.org/10.1016/j.jhep.2004.09.012
  53. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L, American Association for the Study of Liver Diseases United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61(4):1392-1405. https://doi.org/10.1002/hep.27678
  54. Zelber-Sagi S, Kessler A, Brazoswky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R. A double-blind randomized placebo controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4(5):639-644. https://doi.org/10.1016/j.cgh.2006.02.004
  55. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297-2307. https://doi.org/10.1056/nejmoa060326
  56. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135(1):100-110. https://doi.org/10.1053/j.gastro.2008.03.078
  57. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J. Randomized, placebo controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135(4):1176-1184. https://doi.org/10.1053/j.gastro.2008.06.047
  58. Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, Webb A, Portillo-Sanchez P. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305-315. https://doi.org/10.7326/m15-1774
  59. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Natta MV, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685. https://doi.org/10.1056/nejmoa0907929
  60. Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J, the Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN). Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38(2):134-143. https://doi.org/10.1111/apt.12352
  61. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297(8):842-857. https://doi.org/10.1001/jama.297.8.842
  62. Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;341(nov04 1):c5702. https://doi.org/10.1136/bmj.c5702
  63. Klein EA, Thompson Jr IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549-1556. https://doi.org/10.1001/jama.2011.1437
  64. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39(3):770-778. https://doi.org/10.1002/hep.20092
  65. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100(5):1082-1090. https://doi.org/10.1111/j.1572-0241.2005.41583.x
  66. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin GastroenterolHepatol. 2006;4(12):1537-1543.
  67. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rossle M, Cordes HJ, Zeuzem S, Hein J, Berg T, the NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52(2):472-479. https://doi.org/10.1002/hep.23727
  68. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. Efficacy and safety of the famesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145(3):e571.
  69. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E. Famesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956-965. https://doi.org/10.1016/s0140-6736(14)61933-4
  70. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4(5):639-644. https://doi.org/10.1016/j.cgh.2006.02.004
  71. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49(1):80-86. https://doi.org/10.1002/hep.22575
  72. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011;54(5):1610-1619.
  73. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ESH, Nissen SE, Kashyap SR. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med. 2014;370(21):2002-2013.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.